{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:16Z","timestamp":1791994576433,"version":"4.4.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00488","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:35:15Z","timestamp":1521074115000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":57,"title":["Tissue Destruction in Bullous Pemphigoid Can Be Complement Independent and May Be Mitigated by C5aR2"],"prefix":"10.3389","volume":"9","author":[{"given":"Christian M.","family":"Karsten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike M.","family":"Holtsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Tillmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Tofern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska S.","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Nina","family":"Heppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inke R.","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"K\u00f6hl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enno","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,3,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris \u2013 incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","article-title":"Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany","volume":"136","author":"Hubner","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/1523-1747.ep12337492","article-title":"Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies","volume":"109","author":"Zillikens","year":"1997","journal-title":"J Invest Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nm1496","article-title":"Humanization of autoantigen","volume":"13","author":"Nishie","year":"2007","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.4049\/jimmunol.0903101","article-title":"A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen","volume":"184","author":"Ujiie","year":"2010","journal-title":"J Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1172\/JCI116856","article-title":"A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180","volume":"92","author":"Liu","year":"1993","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1046\/j.0022-202x.2001.01683.x","article-title":"Cloning of hamster type XVII collagen cDNA, and pathogenesis of anti-type XVII collagen antibody and complement in hamster bullous pemphigoid","volume":"118","author":"Yamamoto","year":"2002","journal-title":"J Invest Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00403-007-0790-5","article-title":"Experimental models for the autoimmune and inflammatory blistering disease, bullous pemphigoid","volume":"299","author":"Leighty","year":"2007","journal-title":"Arch Dermatol Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1172\/JCI117826","article-title":"The role of complement in experimental bullous pemphigoid","volume":"95","author":"Liu","year":"1995","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1172\/JCI17891","article-title":"Role of different pathways of the complement cascade in experimental bullous pemphigoid","volume":"116","author":"Nelson","year":"2006","journal-title":"J Clin Invest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"15003","DOI":"10.1074\/jbc.M111.221036","article-title":"The C5a receptor on mast cells is critical for the autoimmune skin-blistering disease bullous pemphigoid","volume":"286","author":"Heimbach","year":"2011","journal-title":"J Biol Chem"},{"key":"B14","doi-asserted-by":"publisher","first-page":"7746","DOI":"10.4049\/jimmunol.1000667","article-title":"Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model","volume":"185","author":"Li","year":"2010","journal-title":"J Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.4049\/jimmunol.1003402","article-title":"Antibodies to pathogenic epitopes on type XVII collagen cause skin fragility in a complement-dependent and -independent manner","volume":"188","author":"Natsuga","year":"2012","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrd4657","article-title":"Complement, a target for therapy in inflammatory and degenerative diseases","volume":"14","author":"Morgan","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.ajpath.2014.05.007","article-title":"Fcgamma receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid","volume":"184","author":"Schulze","year":"2014","journal-title":"Am J Pathol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.4049\/jimmunol.1100596","article-title":"Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice","volume":"187","author":"Hirose","year":"2011","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1172\/JCI200521386","article-title":"Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen","volume":"115","author":"Sitaru","year":"2005","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1093\/emboj\/20.12.3046","article-title":"EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG","volume":"20","author":"Collin","year":"2001","journal-title":"EMBO J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jaut.2012.04.002","article-title":"Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII collagen","volume":"39","author":"Hirose","year":"2012","journal-title":"J Autoimmun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/exd.13415","article-title":"In vitro and in vivo models to investigate the pathomechanisms and novel treatments for pemphigoid diseases","volume":"26","author":"Bieber","year":"2017","journal-title":"Exp Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"5043","DOI":"10.4049\/jimmunol.1100796","article-title":"Complement-fixing anti-type VII collagen antibodies are induced in Th1-polarized lymph nodes of epidermolysis bullosa acquisita-susceptible mice","volume":"187","author":"Hammers","year":"2011","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/path.4023","article-title":"Genetic identification and functional validation of FcgammaRIV as key molecule in autoantibody-induced tissue injury","volume":"228","author":"Kasperkiewicz","year":"2012","journal-title":"J Pathol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1038\/jid.2010.230","article-title":"FcgammaRIIA and FcgammaRIIIB are required for autoantibody-induced tissue damage in experimental human models of bullous pemphigoid","volume":"130","author":"Yu","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jaut.2015.05.004","article-title":"Allelic and copy-number variations of FcgammaRs affect granulocyte function and susceptibility for autoimmune blistering diseases","volume":"61","author":"Recke","year":"2015","journal-title":"J Autoimmun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/978-1-62703-724-2_23","article-title":"Functional analysis of C5a effector responses in vitro and in vivo","volume":"1100","author":"Karsten","year":"2014","journal-title":"Methods Mol Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v050.i12","article-title":"nparLD: an R software package for the nonparametric analysis of longitudinal data in factorial experiments","volume":"50","author":"Noguchi","year":"2012","journal-title":"J Stat Softw"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1073\/pnas.0711271105","article-title":"IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions","volume":"105","author":"Collin","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/imr.12473","article-title":"Old dogs-new tricks: immunoregulatory properties of C3 and C5 cleavage fragments","volume":"274","author":"Verschoor","year":"2016","journal-title":"Immunol Rev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.shk.0000105502.75189.5e","article-title":"Role of C5a-C5aR interaction in sepsis","volume":"21","author":"Guo","year":"2004","journal-title":"Shock"},{"key":"B33","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1146\/annurev.immunol.23.021704.115835","article-title":"Role of C5a in inflammatory responses","volume":"23","author":"Guo","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/nm.2862","article-title":"Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1","volume":"18","author":"Karsten","year":"2012","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.4049\/jimmunol.0901005","article-title":"Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer\u2019s disease","volume":"183","author":"Fonseca","year":"2009","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/icb.2016.43","article-title":"Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling","volume":"94","author":"Croker","year":"2016","journal-title":"Immunol Cell Biol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nri3761","article-title":"Complement \u2013 tapping into new sites and effector systems","volume":"14","author":"Kolev","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.immuni.2005.02.006","article-title":"C5a negatively regulates toll-like receptor 4-induced immune responses","volume":"22","author":"Hawlisch","year":"2005","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","first-page":"39677","DOI":"10.1074\/jbc.C500287200","article-title":"An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2","volume":"280","author":"Gerard","year":"2005","journal-title":"J Biol Chem"},{"key":"B41","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm1753","article-title":"Functional roles for C5a receptors in sepsis","volume":"14","author":"Rittirsch","year":"2008","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.molimm.2008.11.001","article-title":"The human complement fragment receptor, C5L2, is a recycling decoy receptor","volume":"46","author":"Scola","year":"2009","journal-title":"Mol Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"7633","DOI":"10.1074\/jbc.M109.092106","article-title":"The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction","volume":"285","author":"Bamberg","year":"2010","journal-title":"J Biol Chem"},{"key":"B44","doi-asserted-by":"publisher","first-page":"6741","DOI":"10.4049\/jimmunol.1000892","article-title":"A critical role for C5L2 in the pathogenesis of experimental allergic asthma","volume":"185","author":"Zhang","year":"2010","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/icb.2016.62","article-title":"Targeting the dark horse of complement: the first generation of functionally selective C5aR2 ligands","volume":"94","author":"Kemper","year":"2016","journal-title":"Immunol Cell Biol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.4049\/jimmunol.1700710","article-title":"Monitoring C5aR2 expression using a floxed tdTomato-C5aR2 knock-in mouse","volume":"199","author":"Karsten","year":"2017","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.4049\/jimmunol.178.10.6514","article-title":"The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita","volume":"178","author":"Mihai","year":"2007","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"J276","DOI":"10.1016\/j.jaut.2009.11.014","article-title":"The complement system in systemic autoimmune disease","volume":"34","author":"Chen","year":"2010","journal-title":"J Autoimmun"},{"key":"B49","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrneph.2017.37","article-title":"Complement in ANCA-associated vasculitis: mechanisms and implications for management","volume":"13","author":"Chen","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.jid.2017.03.037","article-title":"Experimental laminin 332 mucous membrane pemphigoid critically involves C5aR1 and reflects clinical and immunopathological characteristics of the human disease","volume":"137","author":"Heppe","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nrrheum.2017.125","article-title":"The complement system as a potential therapeutic target in rheumatic disease","volume":"13","author":"Trouw","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1046\/j.1523-1747.2000.00141.x","article-title":"Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes","volume":"115","author":"Schmidt","year":"2000","journal-title":"J Invest Dermatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/jid.2008.305","article-title":"IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment","volume":"129","author":"Iwata","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"553","DOI":"10.4049\/jimmunol.1001753","article-title":"FcR-independent effects of IgE and IgG autoantibodies in bullous pemphigoid","volume":"187","author":"Messingham","year":"2011","journal-title":"J Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: the European dermatology forum consensus in collaboration with the European academy of dermatology and venereology","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br J Dermatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/bjd.15649","article-title":"An open, multicenter, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone","volume":"177","author":"Sticherling","year":"2017","journal-title":"Br J Dermatol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/S0140-6736(17)30787-0","article-title":"Rituximab as first-line treatment of pemphigus","volume":"389","author":"Schmidt","year":"2017","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.4049\/jimmunol.137.9.2835","article-title":"Defining the role of complement in experimental pemphigus vulgaris in mice","volume":"137","author":"Anhalt","year":"1986","journal-title":"J Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.4049\/jimmunol.1400095","article-title":"Bullous pemphigoid autoantibodies directly induce blister formation without complement activation","volume":"193","author":"Ujiie","year":"2014","journal-title":"J Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjd.14411","article-title":"Bullous pemphigoid suggestive of complement-independent blister formation with anti-BP180 IgG4 autoantibodies","volume":"175","author":"Dainichi","year":"2016","journal-title":"Br J Dermatol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/bjd.14822","article-title":"Complement in bullous pemphigoid: results from a large observational study","volume":"176","author":"Romeijn","year":"2017","journal-title":"Br J Dermatol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1242\/jcs.124388","article-title":"The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation","volume":"126","author":"Triantafilou","year":"2013","journal-title":"J Cell Sci"},{"key":"B66","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.4049\/jimmunol.169.10.5962","article-title":"Expression and function of C5a receptor in mouse microvascular endothelial cells","volume":"169","author":"Laudes","year":"2002","journal-title":"J Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00488\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T12:21:53Z","timestamp":1693570913000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00488\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,15]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2018.00488"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00488","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732929922.793549775","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,15]]},"article-number":"488"}}